Debate over the commercial viability of Sage Therapeutics, Inc./Biogen, Inc.’s zuranolone isn’t getting any quieter as additional data rolls in. The Phase III CORAL study in major depressive disorder (MDD) met its primary endpoint of rapid onset of anti-depressant effect, with an acceptable safety and tolerability profile, but missed a key endpoint on durability.
The companies unveiled the CORAL data on 16 February, saying that the trial met its primary endpoint of a rapid...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
